Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics’s CLN-619?
The revenue for CLN-619 is expected to reach an annual total of $124 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, …